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Background: Combined antiretroviral therapy has drastically reduced mortality and morbidity of HIV-infected individuals.
Nevertheless long-term toxicity and appearance of viral resistance hampers the prolonged effectiveness of combination
therapy, requiring a continuous input of drugs to replace those utilized in combination regimens. We here investigated
the anti-HIV activity of novel derivatives of the suradista chemical class.
Methods: Compounds were tested on acute HIV-1 infection of activated peripheral blood mononuclear cells. HIV
production was monitored by enzyme-linked immunosorbent assay measuring the protein p24 released in culture
supernatants. Fusion assays were carried out to study the mechanism of action of these compounds. A modified
version of a previously established recombinant vaccinia virus-based assay was used measuring activation of a reporter
gene upon fusion of two distinct cell populations. Flow cytometry was performed in competition assays for the
binding of several antibodies targeting different sites of the viral envelope glycoprotein gp120, or the receptor CD4,
or the coreceptors CXCR4 and CCR5.
Results: Four compounds inhibited replication of a prototypic R5 (BaL) and X4 (IIIB) laboratory-adapted HIV-1 strain at
low micromolar concentrations, in the absence of cytotoxicity. Approximately a ten fold greater activity was achieved
against the X4 as compared to the R5 strain.
The compounds blocked X4 and R5 HIV-1 fusion, a step of viral entry. This activity appeared specific for HIV-1, as entry
of human herpesvirus 6 (HHV-6) and influenza virus was not substantially affected. Further investigation of the inhibitory
mechanism revealed that these new molecules target the viral envelope, rather than the coreceptors, as previously shown
for a congener of the same class characterized by a long plasmatic half-life. Indeed ND-4043, the most active compound,
specifically competed with binding of monoclonal antibodies against the CD4-binding site (CD4-BS) and
coreceptor-binding site (CoR-BS) of gp120. These compounds displayed broad anti-HIV activity, as they inhibited various
primary R5, X4 and, importantly, dualtropic R5X4 HIV-1 isolates. Of the four derivatives tested, the dimeric compounds
were consistently more potent than the monomeric ones.
Conclusions: Given their unique features, these molecules represent promising candidates for further development and
exploitation as anti-HIV therapeutics.Background
Despite the success of global treatment and prevention
strategies, HIV infection rates are still growing world-
wide, and AIDS remains a significant public health bur-
den in low- to middle-income countries. Combination
antiretroviral therapy (ART), encompassing a cocktail of
drugs targeting different steps of the viral life cycle [1],* Correspondence: priscilla.biswas@hsr.it
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disease progression and significantly prolonged life
expectancy of patients. Indeed, current inhibitors include
a wide array of viral targets, such as viral enzymes
(reverse-transcriptase, protease, integrase), viral struc-
tural proteins (gp41), and host cellular components, such
as the chemokine receptor CCR5, which is the major
HIV-1 coreceptor, in addition to CXCR4.
Despite these advancements, mutations in HIV-1 can
arise which confer resistance to drugs, often resulting in
resistance to entire inhibitor classes. Moreover, long-his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Sironi et al. Journal of Translational Medicine  (2015) 13:107 Page 2 of 15term drug toxicity, although reduced in comparison to
early drugs, remains a critical factor in determining the
patient outcome and long-term health. Therefore, it is
evident that clinical management of HIV requires novel
drugs to be continuously available for inclusion in ART
regimens.
Herein, we report the anti-HIV-1 activity of novel syn-
thetic molecules and elucidate their mechanism of ac-
tion. They belong to the suradista chemical class which
shares certain features with the anti-trypanosoma drug
suramin [2,3] and the antibiotic distamycin [4]. Suramin
itself was shown early on to counteract the cytopathic
effect of HIV in vitro [5], but in the following clinical tri-
als it did not result as a clear benefit for AIDS patients
[6,7]. Despite binding to the minor groove of DNA, most
of the biological effects of distamycin were likely due to
the interaction with membrane structures [8]. The anti-
angiogenic activity of suradista molecules has been in-
vestigated in vitro [9] as well as in a clinical phase-I
study for the treatment of cancer [10]. Several sulfonated
and phosphonated suradista molecules have been evalu-
ated as HIV inhibitors [11], and certain congeners have
been shown to interact with HIV coreceptors [12]. We
here demonstrate that novel suradista compounds act as
HIV entry inhibitors targeting critical determinants of
the viral envelope of both R5 and X4 HIV-1 viruses. This
remarkable feature, along with the pharmacokinetic proper-
ties of members of the suradista family, warrants further in-
vestigation and development of these molecules.
Methods
Reagents
The experimental compounds herein tested were dis-
solved in DMSO at a stock concentration of 15 mM, ali-
quoted and frozen at –20°C. The aliquot in use was kept
at room temperature (rt). Control cells always contained
DMSO at a concentration corresponding to that of the
highest concentration of the compounds.
Cells were cultured in complete medium consisting
of RPMI 1640 or DMEM (the latter for fusion assays)
(Euroclone) supplemented with antibiotics penicillin/
streptomicin and glutamin plus 10% heat-inactivated
fetal calf serum (FCS) (Euroclone).
Maraviroc and AMD3100 were obtained from the
Centre for AIDS Reagents, National Institute for Bio-
logical Standards & Control (NIBSC), UK (referred to as
NIBSC, UK).
HIV-1 acute infections
Peripheral blood mononuclear cells (PBMC) were pre-
pared by Ficoll density gradient (Lympholyte H) centri-
fugation of buffy coats from healthy donors. PBMC were
routinely viable at 95-98% and activated with phytoe-
magglutinin (PHA) for 48h. Stock titered preparations ofHIV-1 IIIB and BaL were used in adsorption (30min at
37°C) to infect PHA-activated PBMC, then excess virus
was washed away. Infected cells were maintained in
complete RPMI medium plus IL-2 (Proleukin, Novartis)
at 200 U/ml. Compounds were added prior to adsorption
and then readded in the 96-well culture plates seeded with
PBMC in triplicate. Cell culture supernatant was harvested
at day 4 and 7 post-infection and frozen at -20°C until
tested for viral replication; compounds were replaced at day
4 along with fresh complete medium.
Cytotoxicity assay
PBMC and TZM-bl viability was measured by the MTT
[3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide; Sigma] assay. Cells were seeded in 96-well
plates in three replicates and were incubated for four
(TZM-bl) or six (PBMC) days with different concen-
trations of the compounds or DMSO alone at 0.2% as
control. Then 10μl of complete medium containing
MTT (0.5 mg/ml) was added to each well. After 24h
incubation at 37°C, the supernatant was removed and
200μl of ethanol was added to each well to solubilize
the formazan crystals. After vigorous shaking, absorb-
ance was measured in a microplate reader at 490 nm.
Viral replication assays
The HIV-1 structural protein p24 Gag was measured
by a twin-site sandwich enzyme-linked immunosorbent
assay (ELISA) (Aalto Bio Reagents Ltd, Dublin, Ireland),
based on a previously published method [13]. Briefly,
p24 antigen is captured from a detergent lysate of vi-
rions present in culture supernatants by a sheep poly-
clonal antibody adsorbed to a solid phase (3h incubation
at rt). Bound p24 is detected with a mouse alkaline
phosphatase-conjugated anti-p24 moAb (1h incubation)
and a luminescent detection system. The luminescence
readout gives a broader dynamic range than the colori-
metric readout and allows more accurate quantification
of p24.
In preliminary experiments viral replication was also
measured with the radioactive reverse-transcriptase ac-
tivity assay (RT assay), as previously described [14].
Cell lines
PM1 [15] (from Dr. P. Lusso, AIDS Research and Reference
Program, Division of AIDS, NIAID, NIH, USA; hereafter
referred to as NIH, USA) is a clonal derivative of the hu-
man T lymphocytic HUT 78 cell line characterized by a
unique susceptibility to a wide range of HIV-1 isolates, in-
cluding R5 strains. Sup T1 (NIH, USA, from Dr. J. Hoxie)
is a non-Hodgkin T cell line [16]. MDCK (NIBSC, UK) are
Madin-Darby normal canine kidney cells and HOS is a
human osteosarcoma cell line (NIBSC, UK, from Dr. D.
Littman and Dr. V Kewal Ramni).
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The HIV-1 fusion assay is based on the vaccinia virus T7
RNA polymerase expression system with recombinant
derivatives of the vaccinia virus (v) strain WR obtained
through the NIH, USA [17]. “Effector” or “Donor” cells
are infected with vTF7-3 expressing the bacteriophage
T7 RNA polymerase gene under the control of the v
p7.5 promoter from Dr. T. Fuerst and Dr B. Moss. “Target”
or “Reporter” cells are infected with vCB21R-lacZ, express-
ing the E. coli lacZ gene linked to the bacteriophage
T7 RNA polymerase promoter from Dr. C.C Broder,
Dr P.E. Kennedy and Dr. E.A. Berger. In addition donor
cells express HIV-1 envelope glycoproteins, whereas target
cells also express CD4 plus CXCR4 or CCR5. When donor
and target cells are co-cultured (2h at 37°C) and have the
appropriate HIV entry molecules they fuse, allowing the T7
RNA polymerase to pass from the donor to the target cell,
bind to its promoter and activate the lacZ gene. Subsequent
production of β-galactosidase in the cytoplasm is assessed
by a colorimetric assay of detergent cell lysates with optical
density (OD) as the final read out. In this study the follow-
ing donor cells have been utilized: murine embryo fibro-
blast 3T3 cells (NIH, USA) infected with vaccinia virus
expressing X4 (vCB41) or R5 (vCB43) HIV-1 envelope,
Sup-T1 persistently infected with HIV-1 IIIB (clade B, X4)
and PM1 cells persistently infected with the following
HIV-1 viruses: IIIB (clade B, X4), MN (clade B, X4),
92UG027 (clade D, X4), NP1525 (clade CRF01_AE, X4),
B3-65 (clade B, X4), BaL (clade B, R5), SF162 (clade B, R5),
92BR025 (clade C, R5), 92RW009 (clade A, R5), CM244
(clade E, R5), 92US077 (clade B, R5X4) and HIV-2: 6669
(R5X4). Target cells used in this study were 3T3 cells
stably transfected with CD4 plus CXCR4/CCR5 and the
TZM-bl cell line (NIH, USA, from Dr. John C. Kappes,
Dr. Xiaoyun Wu and Tranzyme Inc.). TZM-bl [18] derived
from a clone of the HeLa (human cervix carcinoma) cell
line that stably expresses large amounts of CD4 and
CCR5, in addition to CXCR4.
Donor and target cells were cultured in DMEM
(Euroclone) plus 2.5% of FCS and incubated for 2h in
the absence or presence of ND-4043 prior to lysis with
NP-40 0.5%, followed by addition of β-galactosidase
substrate and reading absorbency of the plates at
570nm with an ELISA microplate reader (Biorad 680).
In the “wash” experimental conditions the compound
ND-4043 was incubated 30min at 37°C with either
donor or target cells, washed away and not replaced in
the co-culture. The β-galactosidase substrate chlorophenol
red-beta-D-galactopyranoside (CPRG) was purchased from
Roche Applied Sciences.
Flow cytometry
Monoclonal antibodies (moAbs) directed against HIV-1
envelope, CCR5 (clone 2D7) and CXCR4 (clone 12G5,44708, 44716, and 44717) were obtained from NIH,
USA and NIBSC, UK. Indirect immunofluorescence was
performed using phycoerythrin (PE)-conjugated goat
anti-human and anti-mouse immunoglobulins (Southern
Biotech). sCD4 (NIBSC, UK) at 5μg/ml was added to
3T3 cells prior to labelling with 17b and 48d (not
shown) to increase expression of the epitope recognized
by the moAbs. For the competition experiments the
compound ND-4043 was incubated for 30min at rt with
the cells and not washed away prior to addition of
the anti-envelope or the CD4 receptor or coreceptor
antibodies. Unlabeled mouse monoclonal anti-CD4
antibodies used included: 13B8 (Beckman Coulter),
DB81 [19], Leu3A (BD Biosciences), and 3 separate clones
(379, 34924, and 34940) from R&D Systems. Subsequent
secondary antibody staining with anti-mouse (Sigma) was
performed at 4°C for 15min. Acquisition of data (10000
events/sample) was performed with a Gallios (Beckman
Coulter, Inc.) or BD FACS Canto (San Jose, CA) flow
cytometer and analyzed by FlowJo software (Tree Star).
Influenza virus entry assay
A viral entry assay where a β-lactamase protein (Bla)
fused to the influenza matrix protein-1 (M1) was pack-
aged as a structural component into influenza virus-like
particles (VLPs) has been described previously [20].
Briefly, 293T (NIBSC, UK) and MDCK cells were incu-
bated with the compounds at rt 30min prior to infection
with influenza VLPs. Viral entry was then quantified by
adding commercially available CCF2-AM substrate (Life
Technologies) to the infected cells and detecting sub-
strate cleavage by the presence or absence of the Bla
protein. All experiments were performed using a LSRII
flow cytometer (BD Biosciences).
HHV-6 fusion assay
A vaccinia-virus adapted assay was set up to evaluate
fusion mediated by HHV-6 [21]. Donor HSB-2 T cells
(NIH, USA) were infected with cell-free HHV-6 A
(strain GS) and then infected with vTF7-3 expressing the
bacteriophage T7 RNA polymerase gene. Many cell types
have been shown to be permissive to HHV-6-mediated
entry, including HeLa cells. Thus target cells were TZM-
bl infected with vCB21R-lacZ, expressing the E. coli lacZ
gene linked to the bacteriophage T7 RNA polymerase
promoter. The murine anti CD46 moAb J4.48 (Coulter-
Immunotech) was used as a control treatment for blockade
of HHV-6 fusion.
Ethics statement
Anonymized samples of peripheral blood were obtained
from healthy volunteer donors at the Blood Bank of the
San Raffaele Hospital under supervision by the Institutional




The compounds evaluated in the present study were
ND-4040, ND-4041, ND-4042, ND-4043, distamycin itself
(4044) and its close homolog ND-4045. The chemical
structure of the compounds is displayed in Additional file 1:
Table S1.
Inhibition of HIV-1 replication independent of coreceptor
usage
The compounds were tested in HIV-1 infection experi-
ments performed with PHA-activated PBMC derived
from healthy donors. Two laboratory-adapted strains
were used: IIIB, which uses CXCR4 as coreceptor (X4),
and BaL, which requires CCR5 as coreceptor (R5) and
viral replication was measured by p24 ELISA in day 7
culture supernatants (Figure 1). A wide range of concen-
trations were evaluated, from 30 μM to 0.03 μM.
Control cultures contained a concentration of DMSO
equivalent to that of the highest concentration (30 μM)
of the compounds. Distamycin (4044) and ND-4045
were not effective, even at the highest concentrations
tested, whereas compounds ND-4040, ND4041, ND-4042,
ND-4043 were effective against both X4 and R5 HIV-1
viruses at the highest concentrations, but were more
powerful against X4 than R5 (Figure 1). Similar results were
obtained in day 4 culture supernatants (data not shown).
The most active compound was ND-4043, closely followedFigure 1 Effect of the six compounds on HIV-1 replication (left panel
supernatants. Infections were carried out in triplicate cultures in complete me
control which are PBMC in the absence of any compound, but pre-incubated w
of the compound. Values refer to mean ± standard deviation (SD) of 4 indepenby ND-4042, then ND-4040 and at last ND-4041. This
behavior is summarized in Table 1 which displays the
inhibitory concentrations (IC) of the six compounds against
X4 and R5 HIV-1. Inhibition of HIV-1 replication by the
active compounds also at the highest concentrations was
not associated with cytoxicity, as evaluated by the MTT
assay (Table 1).
The activity of ND-4043 was compared to that of two
reference small molecules with selective inhibition on
R5 or X4 replication, maraviroc and AMD3100, respect-
ively (Figure 2). As expected, maraviroc and AMD3100
had no effect on X4 and R5 HIV-1 replication, respect-
ively, at all tested concentration. AMD3100 inhibited X4
HIV-1 replication in a concentration-dependent manner
with complete inhibition up to 0.01 μM, whereas mara-
viroc displayed a complete blockade of R5 HIV-1 replica-
tion at 0.1 μM. ND-4043 inhibited both X4 and R5 HIV-1
replication at 1 μM and 10 μM, respectively.
Studies on the mechanism of antiviral activity
We first evaluated the activity of these compounds at HIV-1
transcriptional and post-transcriptional level employing
HIV-1 chronically infected cell lines, namely ACH-2 [22]
and U1 [23], which offer a high-throughput model system
for evaluating inhibition with good standardization of the
results. Treatment of these cell lines with TNF-α leads to
HIV-1 transcription, through activation of the transcription
factor NF-κB [22], translation and secretion of virions in cul-
ture supernatants. The compounds did not inhibit TNF-α-
induced HIV-1 expression at any concentration in both
cell lines (data not shown). It was concluded that theseX4, right panel R5) measured by the p24 assay on day 7 culture
dium plus 10% of heat-inactivated FCS. Data are reported as percent of
ith DMSO at 0.2%, corresponding to the concentration present in 30 μM
dent experiments each with triplicate cultures.
Table 1 Anti-HIV-1 activity of the compounds
Compound IC50 IC75 IC90 CC50
IIIB (X4)
ND-4040 1.6 2.3 3.0 >30
ND-4041 1.9 5.3 12.6 >30
ND-4042 0.7 0.9 1.4 >30
ND-4043 0.6 0.8 1.0 >30
4044 >30 >30 >30 30
ND-4045 >30 >30 >30 28
BaL (R5)
ND-4040 13.7 21.0 27.2 >30
ND-4041 17.8 >30 >30 >30
ND-4042 2.3 3.2 6.6 >30
ND-4043 2.0 2.6 3.0 >30
4044 >30 >30 >30 25
ND-4045 >30 >30 >30 30
Inhibitory (50, 75 and 90%) and cytotoxic (50%) concentrations (μM) of the six
compounds against X4 and R5 HIV-1 viruses in infected PBMC.
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post-transcriptional level of HIV-1 replication. The latter
was important to investigate since suramin itself was re-
ported to inhibit the reverse–transcriptase of oncogenic
retroviruses [24].
Subsequent experiments were performed to evaluate
the earliest stages of the HIV-1 life cycle, namely fusion
and entry. The compounds were tested in a modified
version of a previously established recombinant vaccinia
virus-based assay [25] that measures activation of a re-
porter gene upon fusion of two distinct cell populations.
The T-cell lines SupT1 and PM1 chronically infectedFigure 2 Comparison of maraviroc, AMD3100 and ND-4043 on inhibit
antigen p24, expressed as ng/ml, is measured at day 7 post infection and d
carried out in complete medium plus 10% of heat-inactivated FCS. Control
concentration present in 30 μM of ND-4043. The tested concentrations of cwith HIV-1 IIIB (X4) and BaL (R5), respectively, were
used as effector cells, whereas TZM-bl were used as tar-
get cells (Figure 3A). As expected, compounds 4044 and
ND-4045 did not affect R5- and X4-mediated fusion also
at the maximum concentration used, whereas the other
four compounds were active. Entry of the X4 virus (left
panel) was inhibited by all four compounds at 30 and 10
μM; ND-4042 and ND-4043 were effective at 3 μM,
but only ND-4043 still exerted 65% inhibition at 1 μM.
Entry of the R5 virus (right panel) was less efficiently
counteracted, in line with the data obtained with viral
replication. The inhibitory activity of ND-4043 on R5
HIV-1-induced fusion was complete at 30 μM and about
50% at 10 μM. The control molecules AMD3100 and
maraviroc selectively blocked entry of X4 and R5 HIV-1,
respectively, in a concentration-dependent manner. Plain
TZM-bl cells (not infected with vaccinia virus to express
the reporter gene) were cultured in the absence and pres-
ence of different concentrations of the six compounds for
four days and cytotoxicity was evaluated by the MTT assay
(Figure 3B). No substantial inhibitory effect was reported
even at the highest concentrations used, underlining the
importance of fusion inhibition.
Of note, inhibition by these compounds of R5 HIV-1
appears less potent in the fusion compared to the PBMC
assay; this is most likely due to CCR5 levels which are
more elevated in TZM-bl cells than in primary PBMCs,
resulting in more efficient fusion kinetics.
A deeper investigation of the mechanism of action at
molecular level was carried out with compound ND-
4043 (Figure 4). A 3T3-based fusion assay was employed
in which 3T3 equipped with appropriate HIV-1 entry
molecules acted as both effector and target cells. This ision of HIV-1 replication (left panel X4, right panel R5). The
ata are reported as mean ± SD of three replicates. Infections were
PBMC were incubated with DMSO at 0.2% corresponding to the
ompounds (ten fold dilutions) are shown in the figure.
Figure 3 Effect of different concentrations of the six compounds plus AMD3100 and maraviroc on HIV-1-mediated fusion (A) and
cytotoxicity (B). Fusion assays were carried out in complete medium plus 2.5% of heat-inactivated FCS with SupT1-IIIB (X4) or PM1-BaL (R5) as
donor cells and TZM-bl as target cells (left panel X4, right panel R5). Viral fusion data, expressed as OD, are presented as mean ± SD of three
replicates on the x axes, whereas concentrations of tested compounds are reported on the y axes. B. MTT assay on day 4 cultures of TZM-bl not
infected with vaccinia virus, in the presence or absence of different concentrations of the six compounds. Data are expressed as OD and represent
mean ± SD of three replicates. Control TZM-bl were incubated with DMSO at 0.2% corresponding to the concentration present in 30 μM of
the compounds.
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do not express endogenous CCR5 or CXCR4, the latter
being expressed endogenously in several human cell
lines, including PM1 and SupT1. The fusion assay was
carried out with three different modalities (Figure 4): as
per protocol, i.e. ND-4043 was added to the co-cultured
3T3 populations and left in the wells throughout the
culture period without washing (“no wash”, bottompanels of X4 and R5 data sets); ND-4043 was incubated
for 30 min only with the donor or target cells, removed by
washing, and then donor and target cells were co-cultured
(“donor–wash” and “target–wash”, respectively). As ex-
pected, inhibition of X4 and R5 HIV-1 entry by ND-4043
was confirmed in the no-wash modality, with the X4
envelope-mediated fusion better inhibited than the R5
counterpart. In the donor-wash condition, inhibition of X4
Figure 4 Differential effect of ND-4043 on donors and targets in HIV-1-mediated fusion (upper panel X4, lower panel R5) entry.
The fusion assay was carried out in complete medium plus 2.5% of heat-inactivated FCS. Both donor and target were 3T3 cells: as donors they
were infected with vaccinia virus expressing X4 (vCB41) or R5 (vCB43) HIV-1 envelope, as targets they were stably transfected with CD4 plus
CXCR4/CCR5. Ctrl = control is the mixture of the donor and target populations of 3T3 cells in the absence of ND-4043. Three incubation conditions
were compared in the same experiment. Viral fusion is expressed as OD and reported data are mean ± SD of three replicates. The compound
ND-4043 is tested at 30, 10, 3 and 1 μM.
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target–wash condition, X4 inhibition was maintained but
R5 inhibition was lost. These results indicate that inhibition
of viral entry by ND-4043 involves the donor more than
the target cell, underlying a potential interaction with the
viral envelope and, to a lesser extent, with the cell receptor
complex formed by CD4 and CXCR4.
Mapping of the HIV-1 envelope region targeted by ND-4043
We took advantage of the availability of several human
moAbs directed against different epitopes of gp120 [26]
to perform flow cytometry experiments aimed at the
characterization of the envelope region targeted by ND-
4043. 3T3 cells infected with vaccinia virus constructs
expressing either X4 (left panel) or R5 (right panel)
envelope were incubated with ND-4043 at three concentra-
tions prior to addition of the human anti-envelope moAbs
(Figure 5A). The broadly neutralizing 2G12 moAb recog-
nizes a unique mannose-dependent epitope on gp120 that
is not directly associated with the receptor-binding sites on
this protein [27]. Neither binding of the anti glycan 2G12
moAb (Figure 5A, upper panels) nor the binding of the anti
gp41 2F5 moAb (data not shown) were affected. Substantial
competition with the anti CD4-binding site (CD4-BS)
moAb 654 [28] was observed with the X4 and, to a lesser
extent, with the R5 envelope expressing cells (Figure 5A,
middle panels). Similar results were obtained with another
anti CD4-BS moAb, b12 [29] (data not shown). Of interest,
the anti coreceptor-binding site (CoR-BS) moAb 17b [30]
was displaced strongly and in a concentration-dependent
manner by ND-4043 on both envelopes (Figure 5A, lower
panels). Similar results were also obtained with another anti
CoR-BS moAb, 48d [30] (data not shown). Moreover, 3T3
cells expressing CXCR4 (left panel) or CCR5 (right panel),
but not HIV-1 envelope, were stained with anti CXCR4 and
anti CCR5 moAbs (Figure 5B). No competition with anti
coreceptor moAb binding was achieved by prior ND-4043
incubation, suggesting that ND-4043 specifically targets
the CoR-BS on the HIV-1 envelope, but not directly the
coreceptors.
Since our earlier experiment (Figure 4) showed that in-
hibition of X4, but not R5, fusion was still achieved
when ND-4043 was incubated only with target cells,
further analyses were performed to evaluate competition
by ND-4043 towards binding of a panel of moAbs di-
rected against CXCR4 (Figure 6A). Treatment of PM1
cells with ND-4043 did not affect binding of four anti-
CXCR4 moAbs, including the one used by Howard et al.
[12] in the study with a congener of this class of mole-
cules. AMD3100 instead inhibited binding of the four
moAbs in a concentration-dependent manner. Similar
results were obtained also with HOS-CXCR4 expressing
cells (data not shown). Finally, ND-4043 at the highest
concentration did not inhibit binding of six different antiCD4 moAbs in PM1 cells (Figure 6B). Taken together, these
data suggest that ND-4043 does not bind to CXCR4 or
CD4 on target cells.
Sensitivity of different viruses to entry inhibition
Given the inhibition of HIV-1 fusion by the active
compounds, we sought to understand whether their
mechanism of action was specific to HIV entry. Influ-
enza viruses infect target cells using a surface glyco-
protein, hemagglutinin, which has fusion and trimerization
properties that resemble those of gp160, but binds to a
different receptor (sialic acid). Entry of influenza A virus
was therefore evaluated by a virus-like particle (VLP)-based
enzymatic assay, with flow cytometry read-out set up for
sensitive detection of viral entry [20]. Entry of influenza
VLPs into canine kidney cells was evaluated (Figure 7A).
Pretreatment of cells with bafilomycin A1, a chemical
inhibitor of endosomal acidification, inhibited viral entry
significantly in canine kidney cells. This effect was specific
to VLP entry, and not due to inhibition of beta-lactamase
substrate entry, as non-infected cells with or without
bafilomycin A1 had similar levels of CCF2AM substrate
present in the cytoplasm after its addition (not shown).
The dimeric compound ND-4043, its monomer ND-4041
and the HIV-1 inactive compound ND-4045, used as
control, showed none or negligible dose-response effects on
influenza A virus entry at any of the tested concentrations.
Similar results were obtained with human embryonic kid-
ney 293 cells (data not shown).
The DNA human herpes virus-6 (HHV-6) binds to
CD46 [21], an ubiquitous immunoregulatory receptor
very different from the receptor for HIV. Thus, fusion
induced by this herpes virus was also evaluated in the
presence and absence of ND-4043 (Figure 7B). Fusion
occured when the T-cell line HSB-2, infected with the
HHV-6 A GS strain, is mixed with the TZM-bl cell line
(Figure 7B), while no fusion occured with uninfected
HSB-2 cells (data not shown). ND-4043 showed negli-
gible inhibition of HHV-6-induced fusion at any of the
tested concentrations, whereas an anti CD46 moAb
inhibited fusion in a concentration-dependent manner.
Breadth of HIV-1 inhibitory activity
The breadth of the HIV-1 inhibitory activity exerted by
the four active compounds was investigated (Figure 8).
To this aim, fusion assays were performed with PM1
cells chronically infected with primary strains of HIV-1
of different clade and tropism as envelope donor cells
and the TZM-bl as target cells expressing host cell re-
ceptors CD4, CXCR4 and CCR5. Four concentrations of
each compound were tested on entry involving 5 X4
(Figure 8A), 5 R5 (Figure 8B) HIV-1 strains, including
the prototypic IIIB (X4) and BaL (R5). In agreement with
the data reported in the present paper, fusion mediated
Figure 5 Flow cytometric analyses in 3T3 cells expressing Env (A) or CXCR4 and CCR5 (B). Three concentrations (30, 10 and 3 μM) of the
ND-4043 compound were used to compete with binding of anti HIV envelope (A) or anti coreceptor (B) moAbs. Incubation with ND-4043 was
carried out in PBS plus 2% of heat-inactivated FCS. DMSO refers to control cells stained with the moAbs but pre-incubated only with DMSO at 0.2%,
corresponding to the concentration present in 30 μM of the compound; uns: unstained cells. A color-coded legend is displayed within the figure.
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one mediated by R5 envelopes. In both cases inhibition
was concentration-dependent. The dimeric compounds
ND-4043 and ND-4042 were the most active inhibitors,
followed by ND-4040 and ND-4041, which acted poorly
on R5 viruses of clade A, C and E.Finally, dualtropic R5X4 viruses were also tested for
sensitivity to inhibition (Figure 8C). ND-4043 and ND-
4042 were comparable in their inhibitory effect, while
ND-4040 and especially ND-4041 were less active in the
cell fusion assay (Figure 8C, two upper panels). ND-
4043 induced a concentration-dependent inhibition of
AB
Figure 6 Flow cytometric analyses in uninfected PM1 cells. ND-4043 is used to compete with binding of 4 anti CXCR4 (A) and 6 anti CD4
(B) moAbs. Incubation with ND-4043 was carried out in PBS plus 2% (A) or 1% (B) of heat-inactivated FCS. A. ND-4043 was used at three
concentrations (30, 10 and 3 μM) and also AMD3100 (3, 0.3 and 0.03 μM). B. ND-4043 was used at 30 μM. DMSO refers to control cells
stained with the moAbs but pre-incubated only with DMSO at 0.2%, corresponding to the concentration present in 30 μM of the compound;
uns: unstained cells. A color coded legend is displayed within the figure.
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in the PBMC infection assay (Figure 8C, three lower
panels).
Discussion
Dystamicin (4044) and the closely related ND-4045
displayed some cytotoxicity and irrelevant HIV inhibi-
tory effect at the concentrations tested in vitro. Con-
versely, four novel compounds, ND-4040, ND-4041,
ND-4042, ND-4043, exerted inhibition of viral replica-
tion in the low micromolar range with no evident
cytotoxicity.
Noteworthy, both X4 and R5 strains of HIV-1 were
inhibited, and X4 consistently more effectively than R5.Experiments assaying the early stages of the viral life
cycle, namely fusion, were consistent with a mechanism
of action of these inhibitory compounds at the level of
viral entry. This is in agreement with a study on a previ-
ous compound of the same class (NSC 651016), which
reported an anti-HIV effect at viral entry [12]. Herein
ND-4043 competes with binding of certain anti HIV en-
velope, but not with binding of anti coreceptor moAbs.
This is a novel finding and differs from earlier data
reporting NSC 651016 to target CCR5 and CXCR4 [12].
Of interest, suramin itself was shown to target a multi-
branched V3 peptide of gp120, inhibiting binding of
HIV-1 envelope to galactosylceramide, the receptor for
HIV-1 in human colon epithelial cells [31].
Figure 7 Effect of compounds on entry of different viruses. A. influenza virus (flu) VLP entry in MDCK cells. ND-4041, ND-4043 and ND-4045
were tested at three concentrations; bafilomycin (100 nM) was used as positive control of flu entry inhibition. Data are expressed as percentage
of control (cells in the absence of compounds) and represent mean ± SD of three replicates of two independent experiments. B. HHV-6 virus-mediated
fusion of HSB-2 and TZM-bl cells. Viral entry is expressed as OD and data are mean ± SD of three replicates. ND-4043 was tested at three
concentrations and the anti CD46 moAb (10, 1, 0.1 and 0.01μg/ml) was used as positive control of entry inhibition. Data are representative
of two independent experiments.
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players and a coordinated sequence of events: binding of
gp120 to the primary receptor CD4, a conformational
change of gp120 leading to binding of the CoR-BS of
gp120 to the CCR5 or CXCR4 coreceptor, unmasking of
gp41 and its insertion into the cell membrane leading to
fusion of the viral and cell membrane and, finally, entry of
the HIV-1 core into the cell [32,33]. We provide evidence
that ND-4043 targets the CD4-BS and the CoR-BS of
gp120 to precisely counteract the initial conformational
changes within the HIV envelope that support successful
viral entry.
It is intriguing how the mechanism of action of
ND-4043 closely resembles that of the human alpha
defensin-5 (HD-5) [34], a peptide of the innate anti-
microbial host defense response, which binds both theCD4-BS and the CoR-BS of gp120. The HIV inhibitory
effect of HD-5 is lost or reduced in the presence of bo-
vine serum in culture. We also observed that inhibition
by a suboptimal concentration of ND-4043 is greatly
enhanced (about 75%) when the HIV fusion assay is
performed in the absence of FCS compared to the
typical 2.5% concentration of FCS (data not shown).
Nevertheless, binding of serum proteins by NSC 651016,
a congener of the suradista class of molecules, may ac-
count for its remarkable stability and long half-life in
plasma, as documented by pharmacokinetic studies in
mice [11] and humans [10].
The current ART armamentarium encompasses two
drugs that act at the entry level, enfuvirtide and mara-
viroc. Enfuvirtide [35], blocks gp41-mediated fusion, the
last step of the HIV entry sequence of events, irrelevant
Figure 8 Breadth of anti-HIV activity by the active compounds. Fusion assays were performed with target TZM-bl cells plus donor PM1 cells
chronically infected with 5 X4 (A), 5 R5 (B) and 2 R5X4 viruses (C). Each panel represents a single experiment carried out with three replicates.
Fusion assays were performed in complete medium plus 2.5% of heat-inactivated FCS. The four active compounds have been tested at the
indicated concentrations. Viral entry is expressed as OD/min and data are reported as mean ± SD of the three replicates. C. The p24 assay,
expressed as ng/ml, was performed with day 7 supernatants from PBMC infected with the three indicated R5X4 viruses and only ND-4043 was
tested (30, 10, 3 μM). Values refer to mean ± SD of three replicates.
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it needs to be delivered twice daily by subcutaneous
injection to obtain therapeutic concentrations, a modalitythat hampers patients’ compliance. Maraviroc [36,37] is
orally bioavailable and, by targeting the CCR5 coreceptor, is
suitable for treatment of patients harboring R5 viruses. R5
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patients harbor dualtropic viruses (R5X4) [38-42]. Thus,
the unique feature of ND-4043 and congeners to inhibit
R5, X4 and R5X4 HIV-1 viruses identifies these compounds
as potentially broad-spectrum treatments. Pure X4 viruses
are rare (around 1-3%), but R5X4 viruses have been found
in about 15-20% of treatment-naïve individuals [38,39] and
in 40-48% of treated and multiexperienced patients [39-42].
An association between non-R5 virus infection and more
rapid CD4 T-cell loss both in treated and ART-naive sub-
jects has been reported [39,43,44]. Importantly, combin-
ation ART including maraviroc requires coreceptor usage
screening [45] of patients’ virus to exclude those who har-
bor R5X4 or X4 viruses. Indeed maraviroc was shown to be
neither superior nor noninferior to placebo in treatment-
experienced patients with non-R5 HIV-1 [46]. Thus the
availability of another drug targeting viral entry, rather than
enfuvirtide, provides a desirable treatment option for a
relatively large proportion of individuals with non-R5
HIV-1 viruses, who are excluded by current maraviroc-
containing ART. Future in vitro investigation is required
to evaluate the inhibitory effect of these compounds tested
together with components of the antiretroviral combin-
ation therapy, including NNRTI/NRTI, PI, integrase inhib-
itors, or investigational compounds currently in clinical
trials such as the attachment inhibitor BMS-378806 [47].
The unique pharmacokinetic profile displayed by mem-
bers of this class of compounds, with terminal plasma
half-life in humans in the order of one month, represents a
substantial treatment advantage for patients, with a signifi-
cant impact on compliance and, consequently, efficacy. In
many instances, pharmacokinetic/pharmacodynamic prop-
erties may represent major determinants in the exploitabil-
ity of certain compounds, rather than potency by itself [48].
Indeed a novel and currently pursued strategy is to provide
long-acting formulations of antiretrovirals [49], as monthly
or bi-monthly injections may provide a safer and more effi-
cacious treatment option to oral dosage.
Another context in which this class of compounds
could be important is vertical mother-to-child transmis-
sion, a significant means of HIV-1 transmission in devel-
oping countries. The efficacy of anti-HIV therapy in
blocking vertical transmission during the perinatal phase
has been documented [50]. However, economic and lo-
gistic problems limit the use of programs for prevention
of vertical transmission. In this context, a long-acting
drug with the potential of twice monthly dosing may
represent an enormous medical advantage.
Discovery and optimization of CXCR4 antagonists as
anti-HIV therapeutics has been attempted; however, the se-
lective X4 entry inhibitor, AMD3100, has been licensed and
marketed as a hemapoietic stem cell mobilizer (Plerixafor)
[51]. Of interest, in the side-by-side comparison performed
in this study AMD3100 and maraviroc were approximately100 fold more active than ND-4043 on X4 and R5 inhib-
ition, respectively. Nevertheless, co-administration of two
separate drugs would be required to exert the broad anti-
HIV effects mediated by ND-4043 alone. Moreover, viro-
logic failure to maraviroc was associated with emergence of
CXCR4-using virus in 57% of subjects in whom a further
tropism test was obtained at the failure time-point [52]. In
the case of ND-4043, which exhibits more potent inhibition
against CXCR4-utilizing viruses, the hypothetical risk of
directing R5X4 strains towards use of CCR5 would result
in the positive outcome of making those viruses more sus-
ceptible to inhibition by maraviroc. A therapeutic strategy
that lately is being proposed is to combine CD4 mimics
[53], inhibitors of the CD4-gp120 interaction, together
with anti coreceptor molecules, or making hybrids [54].
This strategy appears to be recapitulated by the action
of ND-4043 alone which competes for binding of anti
CD4-BS and, to a greater extent, of anti CoR-BS moAbs on
HIV-1 envelope.Conclusions
This study identifies novel inhibitors of HIV-1 entry cap-
able of inhibiting both X4 and R5 viruses. Mechanistic
studies with ND-4043, the most active compound, indi-
cate that inhibition of viral entry involves the CD4-BS
and the CoR-BS on HIV Env. This inhibitor may repre-
sent an important component of combination therapy in
patients with viral resistance to current entry inhibitors and
prove particularly advantageous to those who harbour dual-
tropic R5X4 viruses because of its distinct mechanism of
action. Selectivity of inhibition of HIV entry is highlighted
by the irrelevant effect exerted by ND-4043 on assays
addressing entry of influenza and HHV-6 viruses, both of
which use very different cellular receptors.
ND-4043 is expected to share the favorable pharmaco-
kinetics and low cytotoxicity displayed by a congener of
the same class that has been used in a phase I clinical
trial as an anti-angiogenic agent. Thus, further investiga-
tion is warranted aiming towards development of ND-
4043, or other members of the same class, as potential
anti-HIV-1 drugs.Additional file
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